Search research articles
Contact Us
Filters
Showing results (31-40 of 37) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 37 results.
International Journal of Cancer
|
May 29, 2023
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma
Don Eslin, Peter E Zage, Genevieve Bergendahl, et al.
Cancer Medicine
|
February 28, 2015
Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma
Giselle L Saulnier Sholler, Jeffrey P Bond, Genevieve Bergendahl, et al.
Scientific Reports
|
September 29, 2018
Maintenance DFMO Increases Survival in High Risk Neuroblastoma
Giselle L Saulnier Sholler, William Ferguson, Genevieve Bergendahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2005
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
Paul A Meyers, Cindy L Schwartz, Mark Krailo, et al.
Plos One
|
May 29, 2015
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma
Giselle L Saulnier Sholler, Eugene W Gerner, Genevieve Bergendahl, et al.
Cancer Reports (Hoboken, N.J.)
|
March 31, 2022
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma
Jacqueline M Kraveka, Elizabeth C Lewis, Genevieve Bergendahl, et al.
Genome Medicine
|
February 12, 2024
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial
Giselle L Saulnier Sholler, Genevieve Bergendahl, Elizabeth C Lewis, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 37) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 37 results.
International Journal of Cancer
|
May 29, 2023
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma
Don Eslin, Peter E Zage, Genevieve Bergendahl, et al.
Cancer Medicine
|
February 28, 2015
Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma
Giselle L Saulnier Sholler, Jeffrey P Bond, Genevieve Bergendahl, et al.
Scientific Reports
|
September 29, 2018
Maintenance DFMO Increases Survival in High Risk Neuroblastoma
Giselle L Saulnier Sholler, William Ferguson, Genevieve Bergendahl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 19, 2005
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
Paul A Meyers, Cindy L Schwartz, Mark Krailo, et al.
Plos One
|
May 29, 2015
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma
Giselle L Saulnier Sholler, Eugene W Gerner, Genevieve Bergendahl, et al.
Cancer Reports (Hoboken, N.J.)
|
March 31, 2022
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma
Jacqueline M Kraveka, Elizabeth C Lewis, Genevieve Bergendahl, et al.
Genome Medicine
|
February 12, 2024
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial
Giselle L Saulnier Sholler, Genevieve Bergendahl, Elizabeth C Lewis, et al.
Page
of 4